Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Chinese Patent Office
Express Scripts
Fuji
Argus Health
Johnson and Johnson
UBS
McKesson

Generated: August 15, 2018

DrugPatentWatch Database Preview

Par Pharm Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?

PAR PHARM INC has twenty-eight approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-three supplementary protection certificates in eleven countries.

Summary for Par Pharm Inc
International Patents:9
US Patents:1
Tradenames:27
Ingredients:27
NDAs:28

Drugs and US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc TIZANIDINE HYDROCHLORIDE tizanidine hydrochloride TABLET;ORAL 207170-001 Jan 26, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc TIZANIDINE HYDROCHLORIDE tizanidine hydrochloride CAPSULE;ORAL 207199-003 Mar 14, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,612,367 ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 4,859,692 ➤ Try a Free Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 6,143,775 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg and 20 mg ➤ Subscribe 2008-02-29

Supplementary Protection Certificates for Par Pharm Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90023-0 Sweden ➤ Try a Free Trial PRODUCT NAME: ROSUVASTATIN
12/018 Ireland ➤ Try a Free Trial PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
C/GB04/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
Deloitte
Fish and Richardson
Healthtrust
Moodys
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.